Skip to main content

Ventana Teams with Advanced Cell Diagnostics on Assay Systems

NEW YORK (GenomeWeb News) – Ventana Medical Systems has entered into a worldwide co-promotion agreement with Advanced Cell Diagnostics for a fully automated RNA in situ hybridization assay system.

The alliance automates ACD's RNAscope reagent system on Ventana's Discovery series slide staining platforms. According to Ventana, a member of the Roche Group, the system will be the first fully automated RNA in situ hybridization system "capable of robust detection and visualization of virtually any expressed gene in routine specimens at single-molecule sensitivity."

The partners expect to launch the first products from the alliance in the first quarter of 2012. The firms will initially offer the products for research use only.

Bill Crawford, director of marketing for the Discovery products for Ventana, said in a statement that the combination of the firm's technologies would deliver a "powerful solution for biomarker discovery and validation. …It has significant potential to advance cell- and tissue-based biomarker analyses for future clinical and companion diagnostics development."

Financial and other terms of the alliance were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.